Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jul 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

对于慢性淋巴细胞白血病患者 (LRF CLL4试验) 的fludarabine加环胺的评估:一个随机对照试验.

D Catovsky1, S Richards2, E Matutes1

  • 1Section of Haemato-Oncology, Institute of Cancer Research, Sutton, UK.

Lancet (London, England)
|July 31, 2007
PubMed
概括

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Glucocorticoid resistance in chronic lymphocytic leukaemia is associated with a failure of upregulated Bim/Bcl-2 complexes to activate Bax and Bak.

Cell death & disease·2012
Same author

The use of individualized tumor response testing in treatment selection: second randomization results from the LRF CLL4 trial and the predictive value of the test at trial entry.

Leukemia·2012
Same author

Effect of cell isolation methods and drug concentration on the use of the Differential Staining Cytotoxicity (DiSC) assay with solid tumours.

Cytotechnology·2012
Same author

Similarities simplify.

Irish medical journal·2003
Same author

Haematological safety of antipsychotic drugs.

Expert opinion on drug safety·2003
Same author

"Tinea pseudoimbricata": tinea corporis in a renal transplant recipient mimicking the concentric rings of tinea imbricata.

Clinical and experimental dermatology·2003
此摘要是机器生成的。

弗鲁达拉宾加环胺在慢性淋巴细胞白血病患者的无进展生存期优于单独使用弗鲁达拉宾或氨酸. 这种组合疗法被推为白血病治疗的新标准护理.

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 临床试验 临床试验

背景情况:

  • 以前的研究表明,在慢性淋巴细胞白血病 (CLL) 中,fludarabine和cyclophosphamide的响应率很高.
  • 目前的研究旨在在CLL患者中比较fludarabine加环胺与fludarabine或ambucil的生存益处.

研究的目的:

  • 为了确定是否fludarabine加环胺提供了与fludarabine或ambucil相比更好的生存率.
  • 评估接受不同治疗方案的CLL患者的应答率,无进展生存率,毒性和生活质量.

主要方法:

  • 一项随机对照试验涉及777名慢性淋巴细胞白血病患者.
  • 患者被分配给接受fludarabine,fludarabine加环胺或ambucil的不同时间.
  • 总体存活率是主要终点,次要终点包括应答率,无进展存活率和毒性.

主要成果:

  • 治疗组之间没有观察到总生存时间的显著差异.
  • 与弗鲁达拉宾和酸相比,弗鲁达拉宾加环胺的完全和整体响应率显著更高.
  • 在5年后无进展的存活率与fludarabine加环胺 (36%) 相比fludarabine (10%) 或ambucil (10%) 显著更好.

更多相关视频

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

相关实验视频

Last Updated: Jul 11, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

A BW Reporter System for Studying Receptor-Ligand Interactions
06:05

A BW Reporter System for Studying Receptor-Ligand Interactions

Published on: January 7, 2019

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

  • 弗鲁达拉加环胺疗法在各种年龄组和预后亚组中显示出好处.

    • 结论:

    • 应考虑fludarabine加环胺作为慢性淋巴细胞白血病的标准治疗方法.
    • 这种组合疗法为开发新的治疗方案提供了基础,可能包括单克隆抗体.